Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B <i>Clostridioides difficile</i> Vaccine in Adults 50 Years and Older
Gretchen Crook(Austin Regional Clinic), Nicholas Kitchin(Pfizer (United States)), Stephen Lockhart(Johns Hopkins University), Yahong Peng(Pfizer (United States)), Warren V. Kalina(Pfizer (United States)), Michael W. Pride(Pfizer (United States)), William C. Gruber(Pfizer (United States)), Francine Lowry(Pfizer (United States)), Kenneth Koury(Pfizer (United States)), Annaliesa S. Anderson(Pfizer (United States)), Haiying Zhang(Pfizer (United States)), Erik Lamberth(Pfizer (United States))
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
|New England Journal of Medicine|2015|1.2k